Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences

Rhea-AI Summary

Alimera Sciences, Inc. (Nasdaq: ALIM) announced the presentation of three scientific abstracts at upcoming ophthalmic congresses. The abstracts will focus on safety outcomes and retinal thickness related to the 0.18 mg Fluocinolone Acetonide Intravitreal Implant in patients with Chronic Non-infectious Uveitis. The conferences include the ARVO and RWC, showcasing research by renowned physicians in the field.

ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it will have three scientific abstracts at two upcoming ophthalmic congresses including the Association for Research in Vision and Ophthalmology (ARVO) conference, scheduled in Seattle, WA. from May 5 - 9 and Retina World Congress (RWC) scheduled in Fort Lauderdale, FL. from May 9 - 13.

ARVO Key Abstracts:

• Tue, May 07 8:30am - 10:15am PT; Tedi Begaj, MD; Lisa Faia, MD
  CALM: 24-Month Safety Outcomes From a Real-World Registry Study of Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment Treated with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant (Poster A0170)

• Thu, May 09 2:30pm - 2:45pm PT; Phoebe Lin, MD
  CALM: 24-Month Retinal Thickness Outcomes From a Real-World Registry Study of Patients with Chronic Non-infectious Uveitis Affecting the Posterior Segment Treated with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant (Abstract #6454)

RWC Key Abstract:

• Poster-on-demand, Michael Singer, MD
  36-month Outcomes Following Treatment of Chronic Non-infectious Uveitis Affecting the Posterior Segment with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant: a CALM Registry Analysis

About YUTIQ
YUTIQ is a sustained release fluocinolone acetonide intravitreal implant injected into the back of the eye using CONTINUOUS MICRODOSING™ technology, which is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months, to reduce the recurrence of disease and enable patients to maintain vision longer with fewer injections. YUTIQ helps provide CONTINUOUS CALM™ by reducing recurrence of inflammation in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. For more information, please visit www.YUTIQ.com

About Alimera Sciences, Inc.
Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

For press inquiries: Cassy Dump for Alimera Sciences 619-971-1887 cassy@heyshine.com

For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com

FAQ

What conferences will Alimera present scientific data at?

Alimera will present scientific data at the Association for Research in Vision and Ophthalmology (ARVO) and Retina World Congress (RWC).

What is the focus of the scientific abstracts presented by Alimera?

The abstracts will focus on safety outcomes and retinal thickness in patients with Chronic Non-infectious Uveitis treated with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant.

Who are some of the physicians presenting the research at the conferences?

Physicians like Tedi Begaj, Lisa Faia, Phoebe Lin, and Michael Singer will present research at the upcoming conferences.